A study of Calculus Bovis Sativus for fatty liver disease
Treatments studied
This trial tests a natural substance called Calculus Bovis Sativus to see if it can help people with metabolic fatty liver disease (MAFLD). It aims to improve liver health and reduce fat in the liver.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Aged 18 to 75 years old
- Diagnosed with fatty liver disease related to metabolism
- Significant liver fat seen on a special ultrasound (FibroScan CAP value 240 or higher)
- Liver enzyme levels are somewhat elevated but not too high
- Low risk of advanced liver scarring (fibrosis)
- Stable weight for at least 6 weeks before the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how a specific gut bacteria (Ruminococcus gnavus) and its byproducts are linked to fatty liver disease (MAFLD). It compares people with the condition to healthy individuals to better understand the connection.
This trial is testing a new ultrasound method to measure fat in the liver for people with metabolic fatty liver disease (MAFLD). It may help understand how well ultrasound can show liver fat compared to a liver biopsy or MRI.
This trial tests whether a probiotic mixture can improve liver health in people with moderate fatty liver disease (MASLD). It looks at how the probiotic affects liver fat, inflammation, and metabolism.
This trial tests a new medication for people with fatty liver disease. It will see if the drug can reduce liver fat and improve liver health over several doses.
This trial tests whether a special mix of probiotics can help improve liver health in people with fatty liver disease related to metabolism. It measures changes in liver enzymes, fat, and stiffness over time.
This trial tests whether Fuzheng Huayu tablets can help people with fatty liver disease that has progressed to cirrhosis (scarring) that is still compensated (the liver is still working well). The goal is to see if the tablets slow or reverse liver damage.
Hear when a new Metabolic Dysfunction-associated Fatty Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.